预约演示
更新于：2026-09-07
Fluocinolone Acetonide/Hydroquinone/Tretinoin
氟轻松丙酮酯/氢醌/维A酸
更新于：2026-09-07
概要
基本信息
药物类型 小分子化药 |
别名 Hydroquinone/tretinoin/fluocinolone-acetonide、Tri-Luma、孚立美 |
作用方式 激动剂、抑制剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、RARα激动剂(维甲酸受体α激动剂)、RARβ2激动剂(维甲酸受体β激动剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-01-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30F2O6 |
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N |
CAS号67-73-2 |
查看全部结构式(3)
关联
10
项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床试验IRCT20220919055994N3
Evaluating the Effectiveness of Cispersa Cream Compared to Tri-luma Formulation in the Treatment of Melasma
CTR20244786
评价氟轻松氢醌维A酸乳膏治疗中、重度黄褐斑的疗效和安全性的多中心、随机、双盲、三臂、平行、安慰剂对照临床试验
CTRI/2024/10/075324
A split face study to compare efficacy and safety of Modified Kligman Formula (Hydroquinone 2% + Tretinoin 0.05% + Flucinolone Acetonide 0.01%) with Topical Metformin 30% in the patients with Melasma - A Prospective Comparative Study in Tertiary Care Hospital - NIL
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床结果
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的转化医学
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的专利（医药）
登录后查看更多信息
5
项与 氟轻松丙酮酯/氢醌/维A酸 相关的文献（医药）2026-05-01JAAD case reports
Near-complete clinical improvement of an extensive congenital acantholytic epidermal nevus treated with topical fluocinolone acetonide/hydroquinone/tretinoin (Tri-luma): A case report
Article
作者: Rivera Ocampo, Stefania
2025-05-01Journal of Cosmetic Dermatology
Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI‐LUMA for the Treatment of Moderate‐To‐Severe Melasma in Chinese Patients: A Randomized, Single‐Center, Placebo‐Controlled Trial
Article
作者: Lunfei Liu ; Chengyao Zhu ; Honghua Hu ; Pengfei Zhou ; Hongliang Yao ; Bo Shen ; Xiangke Yu ; Bo Feng
ABSTRACT:
Background:
Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however, the effects of this treatment in the Chinese population remain unclear. Due to the differences between Chinese and Caucasian subjects, further clinical trials in Chinese patients with melasma are needed.
Aim:
To evaluate the efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin creams in Chinese patients with moderate‐to‐severe melasma.
Methods:
We recruited 53 patients who received a generic formulation (triple combination cream, TCC), brand formulation (TRI‐LUMA), or placebo once daily for 8 weeks. In weeks 4 and 8, efficacy was evaluated based on the Melasma Severity Scale and Melasma Area and Severity Index. In addition, safety was assessed based on the incidence and severity of treatment‐emergent adverse events.
Results:
The generic TCC group achieved 52.2% efficacy compared to 57.1% in the TRI‐LUMA group. There was no significant difference in the incidence of adverse effects between the TCC and TRI‐LUMA groups (69.6% and 90.5%, respectively; p > 0.05). The incidence of adverse events in the placebo group was 0%.
Conclusion:
Generic TCC was as effective as TRI‐LUMA and had a similar safety profile in this study of Chinese subjects with moderate‐to‐severe melasma.
2016-11-01Journal of drugs in dermatology : JDD4区 · 医学
The Efficacy of Q-Switched ND:YAG 1064 nm Laser in Recalcitrant Macular Amyloidosis: A Case Report.
4区 · 医学
Article
作者: Khurana, Nevil ; Urman, Christine
Macular amyloidosis typically presents as small, dusky-brown or greyish pigmented macules, the result of altered keratin deposition. Treatment of these hyperpigmented regions with topical and systemic therapies remains challenging, however Q-Switched neodymi- um-doped yttrium aluminum garnet (ND:YAG) laser has proven to be an effective treatment modality to reduce hyperpigmentation. In this case report we investigated the ef cacy of Q-Switched Nd:YAG laser treatment on a 34-year old woman with recalcitrant macular amyloidosis who failed to respond to over-the-counter bleaching creams. The patient was treated with 7 treatment sessions of Q- Switched Nd:YAG laser at one month intervals. According to our photographic analysis and patient self-assessment, the patient ap- peared to improve with each treatment session. Post-recurrence of the lesion after reaction to Triluma ( uocoinolone actetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), the patient has been continuing to respond well to a second round of treatment with Q-switched Nd:YAG laser at 1064 nm. J Drugs Dermatol. 2016;15(11):1456-1458..
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黄褐斑 | 美国 | 2002-01-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 雀斑样痣 | 临床2期 | 智利 | - | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 50 | Cryotherapy (CRY-AC3® device)+Tri-luma (Group 1) | 簾艱範觸艱願艱範壓夢(繭憲蓋衊鑰廠夢齋廠築) = 獵糧顧獵鏇範衊簾顧廠 構鹽觸壓願艱淵顧範齋 (窪選膚簾鹹繭鬱齋獵顧, 7.0) 更多 | - | 2020-09-17 | ||
Cryotherapy (CRY-AC3® device) (Group 2) | 簾艱範觸艱願艱範壓夢(繭憲蓋衊鑰廠夢齋廠築) = 簾構積顧窪衊糧鏇艱鏇 構鹽觸壓願艱淵顧範齋 (窪選膚簾鹹繭鬱齋獵顧, 11.0) 更多 | ||||||
临床4期 | 56 | (Intense Pulsed Light (IPL) / Tri-Luma® Cream) | 鬱襯艱鑰夢簾願鹽構顧 = 簾築憲窪膚積膚簾壓獵 壓遞壓餘積鬱夢糧築壓 (淵廠築鬱蓋鏇選選膚齋, 觸築廠餘窪築簾憲選蓋 ~ 獵膚鹽醖夢顧壓壓衊廠) 更多 | - | 2010-01-11 | ||
Cetaphil (Intense Pulsed Light (IPL) / Inactive Control Cream) | 鬱襯艱鑰夢簾願鹽構顧 = 膚網簾構艱夢鬱積範醖 壓遞壓餘積鬱夢糧築壓 (淵廠築鬱蓋鏇選選膚齋, 醖膚網選範襯簾衊餘廠 ~ 壓繭選範顧鹽獵衊醖艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用